The forum of tumor immunology and immunotherapy decision makers successfully concluded in Shanghai in 2019!

Immunology has made rapid development in the past two decades A large number of patients benefit from anti TNF, anti CD20, anti CTLA and the latest anti PD1 therapeutic drugs As one of the hope of finally conquering cancer, immunotherapy has become a research hotspot in this field, and at present, it has brought significant clinical benefits to some patients In addition, the field of tumor immunology and immunotherapy has made great progress in fully understanding the basic mechanism of tumor immune system interaction and how to apply these knowledge to the development of effective immune based cancer treatment In this context, the cancer immunology and immunotherapy decision maker forum 2019, sponsored by Guoxin decision maker Industry Research Institute, CO sponsored by cancer precision treatment professional committee of China Anti Cancer Association and organized by Shanghai decision maker Economic Consulting Co., Ltd., was held in Shanghai from May 22 to 24, 2019! Nearly 300 basic researchers, clinical doctors and nurses, teachers and students of colleges and universities, practitioners in the field of biotechnology / pharmacy, and guests from investment enterprises gathered to review the development of tumor immunology and the research results of major projects in this field, share the previous breakthroughs under the efforts of many parties, and explore the development direction and possibility of various anti-tumor immunotherapy to tackle tumor diseases! The forum kicked off in a warm speech by Chairman Qin Lunxiu In the theme report of the first day (May 23), director Qin Lunxiu brought the theme report of inflammation immunity and metastasis prevention and treatment to all of you, which brought enlightening and wonderful sharing to the participants; Director Zhang Xiaochun of Tumor Hospital of Affiliated Hospital of Qingdao University listed a number of typical cases of actual tumor immunotherapy and achievements of clinical experience of Qingdao precision immunotherapy center on the spot It provides a case reference for clinical practice research Liu Jie, director of Huashan Hospital Affiliated to Fudan University, and Zhang Hongsheng, teacher of Tongji University Medical School, respectively published their research results and understandings from different perspectives around car-t cell therapy; Zheng Limin, Dean of School of life sciences, Sun Yat sen University, and ye Shenglong, Professor of Sun Yat Sen Hospital Affiliated to Fudan University / the Third Affiliated Hospital of Haijun Military Medical University, respectively, expressed "PD-L1 expression of liver cancer tissue , regulation and clinical significance ", and" clinical research focusing on the microenvironment of liver cancer "made a detailed introduction and sharing on the further promoting role of immunotherapy in individualized precise treatment of liver cancer Wang ShengDian, researcher of Institute of Biophysics, Chinese Academy of Sciences, made a professional analysis and research achievement sharing on how to improve the therapeutic effect of anti-PD-1 antibody tumor with the title of "immunotherapy strategy of l1-21 targeting tumor or tumor specific T cell" Meanwhile, Cheng Xiaodong, director of Clinical Immunology Research Institute of Yueyang Hospital Affiliated to Shanghai University of traditional Chinese medicine, mediated natural drug regulation by PD-1 molecular signal The effective mechanism of tumor control immune escape made a wonderful theme report, and had a positive Q & A interaction with the guests attending the meeting In addition, the conference also invited Ms Li Jing, application and product manager of seahorse, Agilent Technology (China) Co., Ltd., to provide cutting-edge sharing and introduction on innovative detection methods and auxiliary values of energy metabolism platform of Agilent seahorse cells for tumor and immunometabolism research Ms Wang Huijun, as the head of China's legal science department of Bristol Myers Squibb (China) Investment Co., Ltd., has brought the comparative information on the development trend of global immunotherapy and China's immunotherapy for the field experts and enterprises in the near future, and introduced your company's ardent desire and work business for promoting China's immunotherapy On the second day (24 days) of the conference, Li Bin, deputy director of Shanghai Institute of immunology, shared the latest progress in the research on the molecular mechanism of functional plasticity and stability of Foxp3 + regulatory T cells and anti-tumor immunity Deng Hongxin, a researcher from the State Key Laboratory of biological therapy, West China Hospital, Sichuan University, made progress in the research on combined immunotherapy of tumors We have made a systematic and complete sorting and sharing of stage results with the prospect At the same time, the full promotion examiner from Sichuan Center for patent examination and cooperation of Patent Office of State Intellectual Property Office has made a clear interpretation of the patent work of car-t cell therapy technology, and has made a professional answer for the guests on site on the relevant issues of patent application At the conference, Yu Haijun, a teacher from Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences, took "self coordinated immunotherapy targeting tumor microenvironment" as the title, introduced the phased research results of using tumor microenvironment characteristics to design and build an intelligent nano drug delivery system with microenvironment response, so as to achieve the targeted drug delivery at tumor site and the ultimate goal of precise tumor treatment Finally, Qian Youcun, a researcher from Shanghai Institute of nutrition and health, Chinese Academy of Sciences, gave a detailed and systematic introduction to the dual-edged general use of inflammatory cytokines in the microenvironment of anti-tumor immunity and coarse tumor growth, and put forward the opinion and conclusion that its effect mainly depends on different research models and experimental conditions The conference was held by Agilent Technology (China) Co., Ltd., Andy Biotechnology (Shanghai) Co., Ltd., Beckman Kurt Trading (China) Co., Ltd., Shanghai shengzhao Biotechnology Co., Ltd., Beijing Yiqiao Shenzhou Technology Co., Ltd., Beijing Zeping Technology Co., Ltd., Beijing inokai Technology Co., Ltd., and Shanghai Nachi Biotechnology Co., Ltd , strong support from a number of supporting units and media, such as Dexiang Technology Co., Ltd., Bristol Myers Squibb (China) Investment Co., Ltd and Chengdu Yujiang Pharmaceutical Technology Co., Ltd We sincerely thank all the speakers and participants, enterprises and media for their support and recognition of this forum!